Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 17/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17896798 | 0.82 | NPC1 (0.56) | CCR5MAP4K4KMT2ASIGMAR1 | |
| SCHEMBL11626650 | 0.80 | MAP4K4 (0.57) | CCR5MAP4K4KMT2ASIGMAR1 | |
| SCHEMBL19444606 | 0.80 | CCR5 (0.64) | CCR5MAP4K4KMT2A | |
| SCHEMBL12545922 | 0.80 | PARP1 (0.46) | CCR5 | |
| SCHEMBL4283829 | 0.79 | CCR5 (0.62) | CCR5KMT2ASIGMAR1 | |
| SCHEMBL2404441 | 0.76 | NPC1 (0.52) | CCR5MAP4K4KMT2ASIGMAR1 | |
| SCHEMBL11627155 | 0.75 | POLB (0.56) | CCR5MAP4K4 | |
| SCHEMBL13956186 | 0.74 | MEN1 (0.49) | CCR5MAP4K4KMT2ASIGMAR1 | |
| SCHEMBL31705840 | 0.74 | CCR5 (0.50) | CCR5MAP4K4SIGMAR1 | |
| SCHEMBL13434079 | 0.74 | CCR5 (0.63) | CCR5SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9382241-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | DPYD, FANCD2, RECQL | CCR5 701/4885MAP4K4 700/4885KMT2A 437/4885 |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | CCR5 279/4885MAP4K4 662/4885KMT2A 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.